Human papillomavirus HPV Associated Cancer-Pipeline Review, H1 2016

Human papillomavirus HPV Associated Cancer-Pipeline Review, H1 2016


  • Products Id :- GMDHC7706IDB
  • |
  • Pages: 166
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Human papillomavirus (HPV) Associated Cancer-Pipeline Review, H1 2016', provides an overview of the Human papillomavirus (HPV) Associated Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Human papillomavirus (HPV) Associated Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Human papillomavirus (HPV) Associated Cancer

The report reviews pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Human papillomavirus (HPV) Associated Cancer therapeutics and enlists all their major and minor projects

The report assesses Human papillomavirus (HPV) Associated Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Human papillomavirus (HPV) Associated Cancer Overview 9

Therapeutics Development 10

Pipeline Products for Human papillomavirus (HPV) Associated Cancer-Overview 10

Pipeline Products for Human papillomavirus (HPV) Associated Cancer-Comparative Analysis 11

Human papillomavirus (HPV) Associated Cancer-Therapeutics under Development by Companies 12

Human papillomavirus (HPV) Associated Cancer-Therapeutics under Investigation by Universities/Institutes 14

Human papillomavirus (HPV) Associated Cancer-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Human papillomavirus (HPV) Associated Cancer-Products under Development by Companies 18

Human papillomavirus (HPV) Associated Cancer-Products under Investigation by Universities/Institutes 21

Human papillomavirus (HPV) Associated Cancer-Companies Involved in Therapeutics Development 22

3SBio Inc. 22

Admedus Ltd 23

Advaxis, Inc. 24

Antigen Express, Inc. 25

Bionor Pharma ASA 26

Cancer Research Technology Limited 27

Cancer Therapeutics CRC Pty Ltd 28

Chong Kun Dang Pharmaceutical Corp. 29

Etubics Corporation 30

EyeGene, Inc. 31

Formune S.L. 32

Genexine, Inc. 33

Genticel S.A. 34

iBio, Inc. 35

Immunovaccine, Inc. 36

Inovio Pharmaceuticals, Inc. 37

Inthera Bioscience AG 38

Karyopharm Therapeutics, Inc. 39

Kite Pharma, Inc. 40

MedImmune, LLC 41

Novartis AG 42

Onconova Therapeutics, Inc. 43

Oryx GmbH & Co. KG 44

Profectus BioSciences, Inc. 45

Selecta Biosciences, Inc. 46

Shantha Biotechnics Limited 47

Sirnaomics, Inc. 48

Theravectys SA 49

Transgene SA 50

UbiVac, LLC 51

Vaccibody AS 52

Virometix AG 53

ViroStatics, srl 54

VLPbio 55

Human papillomavirus (HPV) Associated Cancer-Therapeutics Assessment 56

Assessment by Monotherapy Products 56

Assessment by Target 57

Assessment by Mechanism of Action 59

Assessment by Route of Administration 61

Assessment by Molecule Type 63

Drug Profiles 65

ABI-1968-Drug Profile 65

AEH-10p-Drug Profile 66

alpelisib-Drug Profile 67

Antibodies to Target E6 for HPV Associated Cancer-Drug Profile 69

Antibodies to Target E7 for HPV Associated Cancer-Drug Profile 70

Cellular Immunotherapy for HPV Associated Cancers-Drug Profile 71

Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer-Drug Profile 72

CerviVax-Drug Profile 74

CKD-12201-Drug Profile 75

CTX-0197195-Drug Profile 76

CTX-0272859-Drug Profile 77

CTX-0291736-Drug Profile 78

DPV-001-Drug Profile 79

DPXE-7-Drug Profile 81

EDA-HPVE7-Drug Profile 82

EG-HPV-Drug Profile 83

ETBX-041-Drug Profile 84

GTL-001-Drug Profile 85

GTL-002-Drug Profile 87

GX-188E-Drug Profile 88

HIV and HPV associated cancer vaccine-Drug Profile 89

human papillomavirus (7-valent) vaccine-Drug Profile 90

human papillomavirus [Serotype 16] vaccine-Drug Profile 91

human papillomavirus vaccine-Drug Profile 92

human papillomavirus vaccine-Drug Profile 93

human papillomavirus vaccine-Drug Profile 94

human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar-Drug Profile 95

INO-3106-Drug Profile 96

INO-3112-Drug Profile 97

Lm-LLO-ISG15-Drug Profile 99

LN-145-Drug Profile 101

NIT-02-Drug Profile 103

NP-001-Drug Profile 104

PVX-01-Drug Profile 105

Recombinant Vector Vaccine for HPV Associated Cervical Cancer-Drug Profile 106

Recombinant Vector Vaccine to Target E7 for HPV Associated Cancer-Drug Profile 107

Recombinant Vector Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia-Drug Profile 108

rigosertib sodium-Drug Profile 109

sdCMV-002-Drug Profile 114

SEL-701-Drug Profile 115

Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers-Drug Profile 116

Small Molecules for Solid Tumors and HPV Associated Cancer-Drug Profile 117

SSS-08-Drug Profile 118

STP-909-Drug Profile 119

STP-911-Drug Profile 120

Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer-Drug Profile 121

TA-CIN-Drug Profile 122

TG-4001-Drug Profile 124

TVGV-1-Drug Profile 126

Vacc-HPV-Drug Profile 127

Vaccine for HPV Associated Cancer-Drug Profile 128

Vaccine for HPV Associated Cancers-Drug Profile 129

Vaccine for HPV Associated Skin Cancer-Drug Profile 130

Vaccine for Human papillomavirus Associated Cervical Cancer-Drug Profile 131

VB-1016-Drug Profile 132

verdinexor-Drug Profile 133

VGX-3100-Drug Profile 134

Vicoryx-Drug Profile 135

VMT-2-Drug Profile 136

Human papillomavirus (HPV) Associated Cancer-Recent Pipeline Updates 137

Human papillomavirus (HPV) Associated Cancer-Dormant Projects 156

Human papillomavirus (HPV) Associated Cancer-Product Development Milestones 158

Featured News & Press Releases 158

Appendix 161

Methodology 161

Coverage 161

Secondary Research 161

Primary Research 161

Expert Panel Validation 161

Contact Us 161

Disclaimer 162

List of Figures

Number of Products under Development for Human papillomavirus (HPV) Associated Cancer, H1 2016 14

Number of Products under Development for Human papillomavirus (HPV) Associated Cancer-Comparative Analysis, H1 2016 15

Number of Products under Development by Companies, H1 2016 16

Number of Products under Investigation by Universities/Institutes, H1 2016 18

Comparative Analysis by Clinical Stage Development, H1 2016 20

Comparative Analysis by Early Stage Products, H1 2016 21

Assessment by Monotherapy Products, H1 2016 60

Number of Products by Top 10 Targets, H1 2016 61

Number of Products by Stage and Top 10 Targets, H1 2016 61

Number of Products by Mechanism of Actions, H1 2016 63

Number of Products by Stage and Mechanism of Actions, H1 2016 63

Number of Products by Top 10 Routes of Administration, H1 2016 65

Number of Products by Stage and Top 10 Routes of Administration, H1 2016 65

Number of Products by Top 10 Molecule Types, H1 2016 67

Number of Products by Stage and Top 10 Molecule Types, H1 2016 67

List of Tables

Number of Products under Development for Human papillomavirus (HPV) Associated Cancer, H1 2016 14

Number of Products under Development for Human papillomavirus (HPV) Associated Cancer-Comparative Analysis, H1 2016 15

Number of Products under Development by Companies, H1 2016 16

Number of Products under Development by Companies, H1 2016 (Contd..1) 17

Number of Products under Investigation by Universities/Institutes, H1 2016 18

Comparative Analysis by Late Stage Development, H1 2016 19

Comparative Analysis by Clinical Stage Development, H1 2016 20

Comparative Analysis by Early Stage Development, H1 2016 21

Products under Development by Companies, H1 2016 22

Products under Development by Companies, H1 2016 (Contd..1) 23

Products under Development by Companies, H1 2016 (Contd..2) 24

Products under Investigation by Universities/Institutes, H1 2016 25

Human papillomavirus (HPV) Associated Cancer-Pipeline by 3SBio Inc., H1 2016 26

Human papillomavirus (HPV) Associated Cancer-Pipeline by Admedus Ltd, H1 2016 27

Human papillomavirus (HPV) Associated Cancer-Pipeline by Advaxis, Inc., H1 2016 28

Human papillomavirus (HPV) Associated Cancer-Pipeline by Antigen Express, Inc., H1 2016 29

Human papillomavirus (HPV) Associated Cancer-Pipeline by Bionor Pharma ASA, H1 2016 30

Human papillomavirus (HPV) Associated Cancer-Pipeline by Cancer Research Technology Limited, H1 2016 31

Human papillomavirus (HPV) Associated Cancer-Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2016 32

Human papillomavirus (HPV) Associated Cancer-Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 33

Human papillomavirus (HPV) Associated Cancer-Pipeline by Etubics Corporation, H1 2016 34

Human papillomavirus (HPV) Associated Cancer-Pipeline by EyeGene, Inc., H1 2016 35

Human papillomavirus (HPV) Associated Cancer-Pipeline by Formune S.L., H1 2016 36

Human papillomavirus (HPV) Associated Cancer-Pipeline by Genexine, Inc., H1 2016 37

Human papillomavirus (HPV) Associated Cancer-Pipeline by Genticel S.A., H1 2016 38

Human papillomavirus (HPV) Associated Cancer-Pipeline by iBio, Inc., H1 2016 39

Human papillomavirus (HPV) Associated Cancer-Pipeline by Immunovaccine, Inc., H1 2016 40

Human papillomavirus (HPV) Associated Cancer-Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 41

Human papillomavirus (HPV) Associated Cancer-Pipeline by Inthera Bioscience AG, H1 2016 42

Human papillomavirus (HPV) Associated Cancer-Pipeline by Karyopharm Therapeutics, Inc., H1 2016 43

Human papillomavirus (HPV) Associated Cancer-Pipeline by Kite Pharma, Inc., H1 2016 44

Human papillomavirus (HPV) Associated Cancer-Pipeline by MedImmune, LLC, H1 2016 45

Human papillomavirus (HPV) Associated Cancer-Pipeline by Novartis AG, H1 2016 46

Human papillomavirus (HPV) Associated Cancer-Pipeline by Onconova Therapeutics, Inc., H1 2016 47

Human papillomavirus (HPV) Associated Cancer-Pipeline by Oryx GmbH & Co. KG, H1 2016 48

Human papillomavirus (HPV) Associated Cancer-Pipeline by Profectus BioSciences, Inc., H1 2016 49

Human papillomavirus (HPV) Associated Cancer-Pipeline by Selecta Biosciences, Inc., H1 2016 50

Human papillomavirus (HPV) Associated Cancer-Pipeline by Shantha Biotechnics Limited, H1 2016 51

Human papillomavirus (HPV) Associated Cancer-Pipeline by Sirnaomics, Inc., H1 2016 52

Human papillomavirus (HPV) Associated Cancer-Pipeline by Theravectys SA, H1 2016 53

Human papillomavirus (HPV) Associated Cancer-Pipeline by Transgene SA, H1 2016 54

Human papillomavirus (HPV) Associated Cancer-Pipeline by UbiVac, LLC, H1 2016 55

Human papillomavirus (HPV) Associated Cancer-Pipeline by Vaccibody AS, H1 2016 56

Human papillomavirus (HPV) Associated Cancer-Pipeline by Virometix AG, H1 2016 57

Human papillomavirus (HPV) Associated Cancer-Pipeline by ViroStatics, srl, H1 2016 58

Human papillomavirus (HPV) Associated Cancer-Pipeline by VLPbio, H1 2016 59

Assessment by Monotherapy Products, H1 2016 60

Number of Products by Stage and Target, H1 2016 62

Number of Products by Stage and Mechanism of Action, H1 2016 64

Number of Products by Stage and Route of Administration, H1 2016 66

Number of Products by Stage and Molecule Type, H1 2016 68

Human papillomavirus (HPV) Associated Cancer Therapeutics-Recent Pipeline Updates, H1 2016 141

Human papillomavirus (HPV) Associated Cancer-Dormant Projects, H1 2016 160

Human papillomavirus (HPV) Associated Cancer-Dormant Projects (Contd..1), H1 2016 161

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

3SBio Inc. Admedus Ltd Advaxis, Inc. Antigen Express, Inc. Bionor Pharma ASA Cancer Research Technology Limited Cancer Therapeutics CRC Pty Ltd Chong Kun Dang Pharmaceutical Corp. Etubics Corporation EyeGene, Inc. Formune S.L. Genexine, Inc. Genticel S.A. iBio, Inc. Immunovaccine, Inc. Inovio Pharmaceuticals, Inc. Inthera Bioscience AG Karyopharm Therapeutics, Inc. Kite Pharma, Inc. MedImmune, LLC Novartis AG Onconova Therapeutics, Inc. Oryx GmbH & Co. KG Profectus BioSciences, Inc. Selecta Biosciences, Inc. Shantha Biotechnics Limited Sirnaomics, Inc. Theravectys SA Transgene SA UbiVac, LLC Vaccibody AS Virometix AG ViroStatics, srl VLPbio

Human papillomavirus (HPV) Associated Cancer Therapeutic Products under Development, Key Players in Human papillomavirus (HPV) Associated Cancer Therapeutics, Human papillomavirus (HPV) Associated Cancer Pipeline Overview, Human papillomavirus (HPV) Associated Cancer Pipeline, Human papillomavirus (HPV) Associated Cancer Pipeline Assessment

select a license
Single User License
USD 2000 INR 145100
Site License
USD 4000 INR 290200
Corporate User License
USD 6000 INR 435300

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com